Drug Trial Radar · NCT01947907
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Jul 2013
Primary completion
Jul 2015
Study completion Sep 2015
Sponsor
- Lead sponsor
- Ascendis Pharma A/SIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A six month study of ACP-001, a long-acting growth hormone product, versus standard human growth hormone therapy. ACP-001 will be given once-a-week, standard human growth hormone (hGH) will be given on a daily basis. The primary aim is to demonstrate safety, pharmacokinetics and pharmacodynamics over a period of six months. A secondary objective is the comparison of height velocity (HV) of the ACP-001 treated groups to the daily hGH treatment group.
Conditions
- Growth Hormone Deficiency (GHD)
Interventions
ACP-001Drug
Once weekly subcutaneous injection
Human Growth HormoneDrug
Once daily subcutaneous injection of human Growth Hormone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Anti-hGH Binding Antibody FormationTime frame: Visit 2 - Visit 5
- Incidence of Anti-hGH Neutralizing Antibody FormationTime frame: Visit 2 - Visit 5
- Number of Subjects Reporting Local Tolerability Events (Assessed by the Patient and Investigator)Time frame: Start of study treatment through Visit 5 (Week 27)
- Cmax of hGHTime frame: 0 hours to 168 hours at Visit 3 (Week 13)
- AUC0-168h of hGHTime frame: 0 hours to 168 hours at Visit 3 (Week 13)
- E-Trough of IGF-1Time frame: 0 hours to 168 hours at Visit 3 (Week 13)
- Emax of IGF-1Time frame: 0 hours to 168 hours at Visit 3 (Week 13)
- AUEC0-168h of IGF-1Time frame: 0 hours to 168 hours at Visit 3 (Week 13)
Locations
36 sites in 14 countries. Site status is shown where the registry gives one.
2nd Children City Clinic
Minsk, Belarus
University Multiprofile Hospital for Active Treatment (UMHAT) "Sv. Marina"
Varna, Bulgaria
Masaryk´s Hospital
Ústí nad Labem, Czechia
El Shatby University Hospital
Alexandria, Egypt
Ain Shams University Hospital
Cairo, Egypt
Cairo University Hospital
Cairo, Egypt
El Mansoura University Hospital
El Mansoura, Egypt
Hôpital des enfants Pellegrin
Bordeaux, France
Hôpital Jeanne de Flandre
Lille, France
Hôpital Femme-Mère-Enfant
Lyon, France
University Hospital Leipzig
Leipzig, Germany
University Children's Hospital Magdeburg
Magdeburg, Germany
Children's Hospital of Athens "P. A. Kyriakou"
Athens, Greece
Buda Children's Hospital
Budapest, Hungary
Heim Pal Children's Hospital
Budapest, Hungary
University of Pecs
Pécs, Hungary
University of Szeged
Szeged, Hungary
University Medical Hospital
Katowice, Poland
Medical University of Lublin
Lublin, Poland
Regional Hospital N°2 Rzeszow
Rzeszów, Poland
Children's Memorial Health Institute Warsaw
Warsaw, Poland
Emergency Clinical Hospital Cluj-Napoca
Cluj-Napoca, Romania
St. Spiridon County Clinic Emergency Hospital
Iași, Romania
Louis Turcanu Emergency Hospital for Children Timisoara
Timișoara, Romania
Federal State Budgetary Institution
Moscow, Russia
St. Petersburg State Pediatric Medical Academy
Saint Petersburg, Russia
Samara State Medical University
Samara, Russia
Bashkir State Medical University
Ufa, Russia
Children's University Hospital
Ljubljana, Slovenia
Ankara University School of Medicine
Ankara, Turkey (Türkiye)
Ege Üniversity
Izmir, Turkey (Türkiye)
Donetsk Regional Children Clinical Hospital
Donetsk, Ukraine
Kharkiv National Medical University
Kharkiv, Ukraine
Institute of Endocrinology and Metabolism
Kiev, Ukraine
Ukrainian Children Specialized Clinical Hospital
Kiev, Ukraine
Odessa National Medical University
Odesa, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.